HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study.

AbstractBACKGROUND:
This study aimed to evaluate the pathological findings and oncological outcomes of deferred radical prostatectomy in patients who initially elected for active surveillance in a Japanese cohort.
METHODS:
We retrospectively analyzed data collected from a multi-institutional prospective observational cohort of the Prostate Cancer Research International: Active Surveillance-JAPAN study between January 2010 and September 2020. Triggers for radical prostatectomy were disease progression based on pathological findings of repeat biopsy and patients' request. The primary end point was evaluation of prostate-specific antigen recurrence-free survival. Secondary end points were overall survival and comparison of pathological and oncological outcomes between patients stratified into immediate or late radical prostatectomy group by time to radical prostatectomy.
RESULTS:
Overall, 162 patients (15.7%) with prostate cancer underwent initial active surveillance followed by radical prostatectomy. The median time to radical prostatectomy was 18 months (interquartile range 14-43.3), and the median postoperative follow-up was 32 months (interquartile range 14-57.5). Prostate-specific antigen recurrence was observed in eight patients (4.9%). The 3-year prostate-specific antigen recurrence-free survival rate was 96.9%. The 5-year overall survival rate was 100%; however, one patient died of another cause. There were no significant differences in pathological findings between immediate and late radical prostatectomy groups. No significant difference in prostate-specific antigen recurrence-free survival was found between the two groups (log-rank p = 0.34).
CONCLUSIONS:
Radical prostatectomy after active surveillance, as an initial treatment option, does not lead to loss of curative chances in Japanese patients with early-stage prostate cancer in the short follow-up period.
AuthorsYoichiro Tohi, Takuma Kato, Masaki Nakamura, Ryuji Matsumoto, Hiroshi Sasaki, Koji Mitsuzuka, Junichi Inokuchi, Katsuyoshi Hashine, Akira Yokomizo, Hirohito Naito, Isao Hara, Norihiko Kawamura, Masaharu Inoue, Hiroshi Fukuhara, Satoru Maruyama, Shinichi Sakamoto, Toshihiro Saito, Shin Egawa, Yoshiyuki Kakehi, Mikio Sugimoto
JournalInternational journal of clinical oncology (Int J Clin Oncol) Vol. 27 Issue 1 Pg. 194-201 (Jan 2022) ISSN: 1437-7772 [Electronic] Japan
PMID34599725 (Publication Type: Journal Article, Observational Study)
Copyright© 2021. Japan Society of Clinical Oncology.
Chemical References
  • Prostate-Specific Antigen
Topics
  • Humans
  • Japan
  • Male
  • Neoplasm Grading
  • Prospective Studies
  • Prostate-Specific Antigen
  • Prostatectomy
  • Prostatic Neoplasms (surgery)
  • Retrospective Studies
  • Watchful Waiting

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: